Home Cart Sign in  
Chemical Structure| 58186-27-9 Chemical Structure| 58186-27-9

Structure of Idebenone
CAS No.: 58186-27-9

Chemical Structure| 58186-27-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Idebenone, a synthetic analog of coenzyme Q10 (CoQ10), can protect mitochondrial membranes against lipid peroxidation and also used as a neuroprotective agent.

Synonyms: CV-2619; Mnesis; Catena, Raxone, Sovrima

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Idebenone

CAS No. :58186-27-9
Formula : C19H30O5
M.W : 338.44
SMILES Code : O=C1C(CCCCCCCCCCO)=C(C)C(C(OC)=C1OC)=O
Synonyms :
CV-2619; Mnesis; Catena, Raxone, Sovrima
MDL No. :MFCD00274552
InChI Key :JGPMMRGNQUBGND-UHFFFAOYSA-N
Pubchem ID :3686

Safety of Idebenone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H332-H335
Precautionary Statements:P261-P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Neonatal rat cardiomyocytes (NRCMs) 5 μM 24 h To evaluate the protective effect of idebenone on DOX-induced cardiomyocyte toxicity, results showed that idebenone significantly improved the viability of DOX-treated cardiomyocytes. Acta Pharm Sin B. 2024 Jun;14(6):2581-2597.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6J male mice DOX-induced cardiotoxicity model Oral gavage 200 mg/kg Once daily for 7 days To evaluate the protective effect of idebenone on DOX-induced cardiotoxicity, results showed that idebenone significantly improved DOX-induced cardiac dysfunction and survival rate. Acta Pharm Sin B. 2024 Jun;14(6):2581-2597.
Drosophila Transgenic Drosophila expressing uN2CpolyG Oral 7, 15, 50 μM Three times per week for 20 days To evaluate the effect of idebenone on motor performance, lifespan, and mitochondrial function in transgenic flies, results showed that 15μM idebenone significantly improved motor performance, extended lifespan, and restored ATP synthesis levels. Proc Natl Acad Sci U S A. 2022 Oct 11;119(41):e2208649119
C57BL/6J mice CCl4-induced liver fibrosis model Intragastric administration 50, 100 or 200 mg/kg Daily administration for 4 weeks Evaluate the therapeutic effect of IDE on liver fibrosis, results showed IDE significantly reduced liver inflammation and collagen accumulation Cell Death Dis. 2024 Aug 20;15(8):602

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03014856 - Completed - -
NCT00224640 Friedreich Ataxia Phase 1 Phase 2 Completed - France ... More >> Necker Hospital Paris, France, 75015 Less <<
NCT03014908 - Completed - Belgium ... More >> Hasselt University Hasselt, Limburg, Belgium, 3500 Less <<
NCT01421381 - Completed - Canada, Quebec ... More >> Hôpital Notre-Dame (CHUM) Montreal,, Quebec, Canada, H2L 4M1 Germany Friedrich Baur Institut Neurologische Klinik und Poliklinik München, Germany, D-80336 United Kingdom Biomedical Research Centre, The Medical School Newcastle upon Tyne, United Kingdom, NE2 4HH Less <<
NCT02774005 Leber's Hereditary Optic Neuro... More >>pathy (LHON) Less << PHASE4 COMPLETED 2021-03-29 Retinal Consultants of Arizona... More >>, Phoenix, Arizona, United States|Palo Alto Medical Foundation, Palo Alto, California, 94040-2833, United States|Stanford Byers Eye Institute, Stanford, California, 94303, United States|University of Colorado Health Eye Center, Aurora, Colorado, United States|Emory University Hospital, Atlanta, Georgia, 30322, United States|Bethesda Neurology, LLC, Bethesda, Maryland, United States|Washington University, Saint Louis, Missouri, 63110, United States|New York Eye and Ear Infirmary, New York, New York, 10003, United States|University of Virginia, Charlottesville, Virginia, 22903, United States|AKH - Medizinische Universitaet Wien, Wien, Austria|CHU Saint-Pierre, Brussels, Belgium|Cliniques Universitaire Saint-Luc, Brussels, Belgium|UZ Leuven - Campus Sint-Rafa?l, Leuven, Belgium|C. H. U. Sart Tilman, Liège, Belgium|UMHAT "Alexandrovska" EAD, Sofia, Bulgaria|Friedrich-Baur-Institut, Muenchen, Germany|Università di Bologna-Clinica Neurologica-Dipartimento di Scienze Neurologiche, Bologna, Italy|SPZOZ Spital Uniwersytecki w Krakowie, Oddzial Kliniczny Okulistyki i Onkologii Okulistycznej, Krakow, 31-501, Poland|Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego, Poznań, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 2 PUM w Szczecinie, Szczecin, Poland|Samodzielny Publiczny Kliniczny Szpital Okulistyczny, Warszawa, Poland|Uniwersytecki Szpital Kliniczny, Wroc?aw, Poland|Centro Hospitalar de S?o Jo?o, EPE, Porto, Portugal|Institut Catala de Retina, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|University Hospital of Wales, Cardiff, United Kingdom|Moorfields Eye Hospital, London, United Kingdom|Manchester Royal Eye Hospital, Manchester, United Kingdom|Queen's Hospital, Romford, United Kingdom Less <<
NCT01495715 Leber's Hereditary Optic Neuro... More >>pathy Less << Phase 3 Withdrawn - -
NCT00015808 Friedreich Ataxia PHASE1 COMPLETED 2025-04-06 National Institute of Neurolog... More >>ical Disorders and Stroke (NINDS), Bethesda, Maryland, 20892, United States Less <<
NCT02887443 Drug-Drug Interaction Phase 1 Completed - France ... More >> Eurofins Optimed Gières, France, 38610 Less <<
NCT00078481 Friedreich Ataxia PHASE1 COMPLETED 2025-04-06 National Institute of Neurolog... More >>ical Disorders and Stroke (NINDS), Bethesda, Maryland, 20892, United States Less <<
NCT00654784 Duchenne Muscular Dystrophy (D... More >>MD) Less << Phase 2 Completed - Belgium ... More >> Children's Hospital, University Hospital Leuven, Belgium Less <<
NCT02771379 Leber's Hereditary Optic Neuro... More >>pathy (LHON) Less << COMPLETED 2021-04-16 Universitaetsklinikum Graz, Gr... More >>az, 8036, Austria|Medical University of Vienna, Vienna, Austria|CHU de N?mes - H?pital Carémeau, N?mes, Gard, 30029, France|CHU Angers - H?pital H?tel Dieu, Angers, Maine Et Loire, 49033, France|Hopital Roger Salengro - CHU Lille, Lille, Nord, 59037, France|H?pital Européen Georges Pompidou, Paris, Paris Cedex 15, 75908, France|CHU Amiens - Centre Saint Victor, Amiens, Somme, 80054, France|Hopital Neurologique Pierre Wertheimer, Lyon Cedex, 69677, France|Hospices Civils de Lyon, Lyon, 69002, France|Centre Hospitalier National d'Ophtalmologie (CHNO) des Quinze-Vingts, Paris, 75012, France|Fondation Ophtalmologique Adolphe de Rothschild, Paris, 75019, France|Julius Maximilians University, Wuerzburg, Bavaria, 97070, Germany|Universitaetsklinikum Essen, Essen, Germany|Universitaetsklinikum Freiburg, Freiburg, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, 20246, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Friedrich-Baur-Institut, Munich, Germany|Universitaetsklinikum Muenster, Munster, Germany|Dietrich-Bonhoeffer-Klinikum Neubrandenburg, Neubrandenburg, Germany|Universitaetsklinikum Regensburg, Regensburg, Germany|Athens Ophthalmological Center, Athens, 11528, Greece|Università di Bologna-Clinica Neurologica-Dipartimento di Scienze Neurologiche, Bologna, 40123, Italy|Ospedale San Raffaele, Milano, 20132, Italy|Azienda Ospedaliera S. Camillo Forlanini, Rome, 00152, Italy|Universitair Medisch Centrum Groningen, Groningen, 9713 GZ, Netherlands|Maastricht University Medical Center, Maastricht, 6211 LK, Netherlands Less <<
NCT01854359 Multiple Sclerosis|Primary Pro... More >>gressive Multiple Sclerosis Less << PHASE1|PHASE2 COMPLETED 2018-10-31 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT00537680 Friedreich's Ataxia Phase 3 Completed - United States, California ... More >> David Geffen School of Medicine, UCLA Los Angeles, California, United States, 90095-1769 United States, Pennsylvania The Children's Hopsital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT00654784 - Completed - -
NCT00950248 Primary Progressive Multiple S... More >>clerosis Less << Phase 1 Phase 2 Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00537680 - Completed - -
NCT00229632 Friedreich Ataxia PHASE2 COMPLETED 2007-12-17 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT00747487 Leber's Hereditary Optic Neuro... More >>pathy Less << Phase 2 Completed - Canada, Quebec ... More >> Unité de recherche clinique Ophtalmologie- Hopital Notre-Dame Montreal, Quebec, Canada, H2L 4M1 Germany Klinikum der Universität München - Grosshadern, Neurologische Klinik und Poliklinik Munich, Germany, 81377 United Kingdom Clinical Research Facility, 4th Floor Leazes Wing, Royal Victoria Infirmary Newcastle Upon Tyne, United Kingdom, NE1 4LP Less <<
NCT02814019 Duchenne Muscular Dystrophy (D... More >>MD) Less << Phase 3 Recruiting August 2019 -
NCT00905268 - Completed - -
NCT00697073 Friedreich's Ataxia PHASE3 COMPLETED 2025-05-10 David Geffen School of Medicin... More >>e, UCLA, Los Angeles, California, 90095-1769, United States|The Children's Hopsital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States Less <<
NCT00697073 Friedreich's Ataxia PHASE3 COMPLETED 2025-05-10 David Geffen School of Medicin... More >>e, UCLA, Los Angeles, California, 90095-1769, United States|The Children's Hopsital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States Less <<
NCT01027884 Muscular Dystrophy, Duchenne ... More >> Ambulatory Care Less << Phase 3 Completed - -
NCT01027884 - Completed - -
NCT00905268 Friedreich's Ataxia Phase 3 Completed - Austria ... More >> Universitätsklinik Innsbruck Innsbruck, Austria, 6020 Belgium Hôpital Erasme - Université Libre de Bruxelles Bruxelles, Belgium, 1070 France Hôpital de la Salpêtrière - INSERM U679, Neurologie et Thérapeutique expérimentale Paris, France, 75651 Germany HELIOS Klinikum BerlinBuch Berlin, Germany, 13125 Neurologische Universitätsklinik und Poliklinik- Universitätsklinikum Bonn Bonn, Germany, 53105 Klinik II, Neuropädiatrie u.Muskelerkrankungen- Universitätsklinik Freiburg Freiburg, Germany, 79106 Zentrum für Neurologische Medizin Göttingen, Germany, 37073 UKE Hamburg Neuropädiatrie-Zentum für Frauen, Kinder und Jugendmedizin Hamburg, Germany, 20246 Neurologische Klinik- klinikum Grosshadern München, Germany, 81377 Neurologische Universitätsklinik und Poliklinik Tübingen, Germany, 72076 Netherlands University Medical Center Groningen Groningen, Netherlands, 9700 RB United Kingdom National Hospital for Neurology & Neurosurgery London, United Kingdom, WC1N 3BG University of Newcastle upon Tyne -Mitochondrial Research Group Newcastle, United Kingdom, NE2 4HH Less <<
NCT00993967 Freidreich's Ataxia Phase 3 Completed - Austria ... More >> Universitätsklinik Innsbruck Innsbruck, Austria Belgium Hôpital Erasme - Univeristé Libre de Bruxelles Bruxelles, Belgium, 1070 France Hôpital de la Salpétrière - INSERM U679, Neurologie et Thérapeutique expérimentale Paris, France, 75651 Germany HELIOS Klinikum Berlin Berlin, Germany, 13125 Neurologische Universitätsklinik und Ploklinik - Universitätsklimikum Bonn Bonn, Germany, 53105 Klinik II, Neuropädiatrie und Muskelerkrankungen - Universitätsklinik Freiburg Freiburg, Germany, 79106 Zentrum für Neurologische Medizin Göttingen, Germany, 37073 UKE Hamburg Neuropädiatrie - Zentrum für Frauen, Kinder und Jugendmedizin Hamburg, Germany, 20246 Neurologische Klinik - Klinikum Grosshadern München, Germany, 81377 Neurologische Universitätsklinik und Poliklinik Tübingen, Germany, 72076 Netherlands University medical Center Groningen Groningen, Netherlands, 9700 RB Less <<
NCT00758225 Duchenne Muscular Dystrophy PHASE2 COMPLETED 2025-01-11 University Hospitals Leuven, L... More >>euven, 3000, Belgium Less <<
NCT00887562 - Completed - -
NCT00993967 - Completed - -
NCT03727295 Oxidative Stress is an Importa... More >>nt Cause of Parkinson's Disease Less << Phase 4 Not yet recruiting May 30, 2021 -
NCT01303406 Friedreich's Ataxia Phase 3 Completed - Austria ... More >> Innsbruck, Austria Germany Bonn, Germany München, Germany Tübingen, Germany Netherlands Groningen, Netherlands United Kingdom The National Hospital, University College London London, United Kingdom, WC 1N 3BG Less <<
NCT03433807 Duchenne Muscular Dystrophy NO_LONGER_AVAILABLE - Phoenix Children's Hospital, P... More >>hoenix, Arizona, 85016, United States|Yale New Haven Hospital, New Haven, Connecticut, 06510, United States|Lurie Children's Hospital of Chicago, Chicago, Illinois, 60611, United States|University of Iowa, Iowa City, Iowa, 52242, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Kennedy Krieger, Baltimore, Maryland, 21287, United States|Columbia University Pediatric Neuromuscular Center, New York, New York, 10032, United States|Carolina's Healthcare System, Charlotte, North Carolina, 28207, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States|University of Virginia Children's Hospital, Charlottesville, Virginia, 22904, United States|St. Luke's Rehabilitation Institute, Spokane, Washington, 99202, United States Less <<
NCT00887562 MELAS Syndrome Phase 2 Completed - United States, New York ... More >> Columbia University Medical Center New York, New York, United States, 10032 Less <<
NCT03603288 Duchenne Muscular Dystrophy Phase 3 Recruiting January 2022 United States, Minnesota ... More >> Gillette Children's Specialty Healthcare Recruiting Saint Paul, Minnesota, United States, 55101 Contact: Randel Richardson, MD          Belgium University Hospital Leuven Recruiting Leuven, Belgium, 3000 Contact: Gunnar Buyse, MD          Principal Investigator: Gunnar Buyse, MD          CHR Citadelle Recruiting Liège, Belgium, 4000 Principal Investigator: Laurent Servais, MD          Italy Fondazione IRCCS Eugenio Medea Recruiting Bosisio Parini, Italy, 23842 Contact: Maria Grazia Nadia D'Angelo, MD          Principal Investigator: Maria Grazia Nadia D'Angelo, MD          Switzerland Center for neuromuscular disorders, Universitäts-Kinderspital beider Basel (UKBB) Recruiting Basel, Switzerland, 4301 Principal Investigator: Andrea Klein, MD          United Kingdom Robert Jones and Agnes Hunt Orthopaedic Hospital Recruiting Oswestry, United Kingdom, SY10 7AG Contact: Tracey Willis, MD          Principal Investigator: Tracey Willis, MD Less <<
NCT01303406 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.95mL

0.59mL

0.30mL

14.77mL

2.95mL

1.48mL

29.55mL

5.91mL

2.95mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories